The role of inflammation in cadmium nephrotoxicity: NF-κB comes into view
Kidney diseases are major health problem and understanding the underlined mechanisms
that lead to kidney diseases are critical research points with a marked potential impact on …
that lead to kidney diseases are critical research points with a marked potential impact on …
Inhibitors of phosphodiesterase as cancer therapeutics
T Peng, J Gong, Y Jin, Y Zhou, R Tong, X Wei… - European journal of …, 2018 - Elsevier
Phosphodiesterases (PDEs) are a class of enzymes that hydrolyze cyclic adenosine
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) which is involved in …
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) which is involved in …
Houttuynia cordata Thunb. and its bioactive compound 2-undecanone significantly suppress benzo(a)pyrene-induced lung tumorigenesis by activating the Nrf2-HO-1 …
Y Lou, Z Guo, Y Zhu, M Kong, R Zhang, L Lu… - Journal of Experimental …, 2019 - Springer
Background Lung cancer remains the most common cause of cancer-related deaths, with a
high incidence and mortality in both sexes worldwide. Chemoprevention has been the most …
high incidence and mortality in both sexes worldwide. Chemoprevention has been the most …
Novel redox-sensitive thiolated TPGS based nanoparticles for EGFR targeted lung cancer therapy
MK Viswanadh, N Agrawal, S Azad, A Jha… - International Journal of …, 2021 - Elsevier
Novel glutathione (GSH) redox-sensitive thiolated vitaminE-PEG1000-succinate (TPGH-SH)
was synthesized by conjugating TPGS with 4-amino thiophenol (4-ATP) and confirmed by …
was synthesized by conjugating TPGS with 4-amino thiophenol (4-ATP) and confirmed by …
Therapeutic opportunities in colon cancer: Focus on phosphodiesterase inhibitors
A Mehta, BM Patel - Life sciences, 2019 - Elsevier
Despite novel technologies, colon cancer remains undiagnosed and 25% of patients are
diagnosed with metastatic colon cancer. Resistant to chemotherapeutic agents is one of the …
diagnosed with metastatic colon cancer. Resistant to chemotherapeutic agents is one of the …
Formulation and in vivo efficacy study of cetuximab decorated targeted bioadhesive nanomedicine for non-small-cell lung cancer therapy
Aim: To design, optimize and evaluate docetaxel-loaded chitosan nanoparticles with
(targeted) and without (nontargeted) cetuximab conjugation for the treatment of non-small …
(targeted) and without (nontargeted) cetuximab conjugation for the treatment of non-small …
Protective effect of quercetin, a Flavonol against benzo (a) pyrene-induced lung injury via inflammation, oxidative stress, angiogenesis and Cyclooxygenase-2 …
Quercetin (Qu) is an important polyphenolic flavonoid which exhibits tremendous
antioxidant, anti-inflammatory and other health promoting effects. The aim of the current …
antioxidant, anti-inflammatory and other health promoting effects. The aim of the current …
Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer
S Zhang, D Yun, H Yang, M Eckstein, GD Elbait… - Cell Death …, 2024 - nature.com
Pancreatic cancer is a malignant tumor of the digestive system. It is highly aggressive, easily
metastasizes, and extremely difficult to treat. This study aimed to analyze the genes that …
metastasizes, and extremely difficult to treat. This study aimed to analyze the genes that …
Roflumilast enhances cisplatin‐sensitivity and reverses cisplatin‐resistance of ovarian cancer cells via cAMP/PKA/CREB‐FtMt signalling axis
S Gong, Y Chen, F Meng, Y Zhang, C Li… - Cell …, 2018 - Wiley Online Library
Objective We previously demonstrated the roflumilast inhibited cell proliferation and
increased cell apoptosis in ovarian cancer. In this study, we aimed to investigate the roles of …
increased cell apoptosis in ovarian cancer. In this study, we aimed to investigate the roles of …
Roflumilast: a potential drug for the treatment of cognitive impairment?
Phosphodiesterase-4 regulates the intracellular level of cAMP. Roflumilast, a selective PDE-
4 inhibitor was the first agent in this class to have reached the market for patients with …
4 inhibitor was the first agent in this class to have reached the market for patients with …